Fundraising for Mission Bio to broaden the scope of their Single-Cell Tri-omics platform
Mission Bio, a leading biotech company specializing in single-cell analysis, has announced significant developments following a recent funding round. The investment, led by Ally Bridge Group, will support three key initiatives: Commercial Expansion and Partnerships, Development of Single-Cell Tri-omics Capabilities, and Accelerated Clinical Adoption.
The new appointment of Matthew H. Cato as the Chief Commercial Officer at Mission Bio marks a strategic move to bolster commercial growth, particularly targeting pharmaceutical companies developing cancer therapies. This expansion aims to meet the growing demand for Mission Bio's innovative solutions.
One of the primary objectives of the funding is to advance Mission Bio's platform from dual-omics (DNA and protein) to tri-omics by adding targeted RNA analysis. This upgrade will allow for simultaneous profiling of DNA, RNA, and protein from single cells, improving understanding of cancer biology and therapy resistance.
Another key focus is accelerating the clinical adoption of Mission Bio's Tapestri Platform. The funding will facilitate the expansion of the platform's use in multiple cancer areas, including multiple myeloma, myeloid malignancies, and CAR T-cell therapies. The goal is to provide a comprehensive solution, facilitating personalized treatment guidance for clinicians.
The Tapestri Platform's ability to offer a solution from sample to answer will be instrumental in addressing critical unmet needs in cancer research and treatment. The funding will also aid in the clinical adoption of Mission Bio's platform, helping to bring personalized medicine to the forefront of cancer care.
Brian Kim, CEO of Mission Bio, expressed his excitement about the investment, stating it validates their leadership position in single-cell multi-omics. He added that the investment will help Mission Bio to expand its commercial footprint and provide crucial insights for making treatment decisions in cancer research.
The funding round follows the launch of Mission Bio's Single-Cell Targeted Genotype and Gene Expression assay last month, capable of profiling DNA and RNA in over 10,000 cells. This assay represents a step towards the tri-omics capability that Mission Bio aims to achieve.
Kevin Reilly, Managing Director at Ally Bridge Group, expressed continued conviction that Mission Bio's technology will become essential infrastructure for precision medicine. He believes that the company's single-cell tri-omics platform is a transformative life science innovation that will revolutionize the way we approach cancer research and treatment.
In conclusion, the funding secured by Mission Bio will enable the company to expand its commercial partnerships, develop single-cell tri-omics capabilities, and accelerate clinical adoption of its Tapestri Platform. These initiatives are expected to significantly contribute to the advancement of cancer research and the development of personalized cancer therapies.
- The investment secured by Mission Bio will be instrumental in developing single-cell tri-omics capabilities, allowing for simultaneous profiling of DNA, RNA, and protein from single cells, which can improve our understanding of medical-conditions like cancer and therapy resistance in health-and-wellness.
- To facilitate personalized treatment guidance for clinicians, the funding will accelerate the clinical adoption of Mission Bio's Tapestri Platform, particularly in areas such as multiple myeloma, myeloid malignancies, and CAR T-cell therapies, where the technology could have a transformative impact on the treatment of technology-driven medical-conditions like cancer.
